Kaveh Samani, MD
Internal Medicine · Houston, TXNPI 1720118458
Payments from drug & device makers
Across 190 payments — averaging $46.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$6K
- Amgen$445
- AstraZeneca$416
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$257
- Johnson & Johnson$214
- Bayer$199
- plus $2K from 24 others
What the payments were for
- Food & beverage$8,854100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 40 | $5,792 |
| Amgen(2 entities) | 20 | $445 |
| AstraZeneca | 23 | $416 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 17 | $257 |
| Johnson & Johnson | 14 | $214 |
| Bayer | 9 | $199 |
| GSK | 10 | $194 |
| Ardelyx, Inc. | 6 | $171 |
| Vifor Pharma, Inc. | 6 | $120 |
| Astellas Pharma US Inc | 6 | $117 |
| Novo Nordisk | 4 | $99 |
| Cardiovascular Systems Inc. | 1 | $91 |
| Lilly USA, LLC | 3 | $79 |
| Pfizer | 5 | $77 |
| Dexcom, Inc. | 3 | $73 |
| Boehringer Ingelheim | 3 | $68 |
| Novartis | 2 | $65 |
| Exact Sciences | 3 | $55 |
| Evoke Pharma, Inc. | 2 | $38 |
| Scilex Pharmaceuticals Inc. | 2 | $37 |
| Medtronic | 1 | $36 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Sanofi | 1 | $29 |
| Calliditas Therapeutics US Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $26 |
| Aurinia Pharma U.S., Inc. | 1 | $25 |
| Akebia Therapeutics Inc | 1 | $23 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| AbbVie | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Quadra Assura CRT Defibrillator$1,913
- GALLANT$1,476
- Fortify Assura$530
- Fortify Assura, Ellipse ICD$492
- UNIFY ASSURA$291
- ACCENT$182
- QUADRA ASSURA$177
- Quartet CRT Lead$176
- Confirm Rx$168
- Quadra Allure MP RF CRT Pacemkr$162
- KRYSTEXXA$109
How this compares
$8,854 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 149 | $131,908 |
| MounjaroTirzepatide | 100 | $108,223 |
| FarxigaDapagliflozin Propanediol | 95 | $97,366 |
| OzempicSemaglutide | 78 | $96,629 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 17 | $77,539 |
| JardianceEmpagliflozin | 61 | $71,157 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 14 | $44,611 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 55 | $38,907 |
| LinzessLinaclotide | 26 | $27,987 |
| TradjentaLinagliptin | 24 | $19,669 |
| Breo ElliptaFluticasone/Vilanterol | 34 | $14,962 |
| Spiriva HandihalerTiotropium Bromide | 16 | $13,428 |
| EntrestoSacubitril/Valsartan | 14 | $12,099 |
| XareltoRivaroxaban | 11 | $9,737 |
| Enoxaparin Sodium | 11 | $7,747 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $77 | $133,267164 claims |
| Lilly USA, LLCMounjaro | $79 | $108,223100 claims |
| AstraZenecaFarxiga, Symbicort | $416 | $102,079116 claims |
| Novo NordiskOzempic | $99 | $96,62978 claims |
| Boehringer IngelheimJardiance, Tradjenta | $68 | $90,82685 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $194 | $53,86989 claims |
| AbbVieLinzess | $16 | $27,98726 claims |
| NovartisEntresto | $65 | $12,09914 claims |
| Johnson & JohnsonXarelto | $214 | $9,73711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Houston
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Aung NaingHouston$30.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Nicholas ShortHouston$17.6M
- Isabella GlitzaHouston$14.8M
- Murtaza MussajiHouston$13.1M
- Hussein TawbiHouston$12.6M
- Hans LeeHouston$11.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.